Arcturus Therapeutics Holdings Inc (ARCT)
16.91
-0.16
(-0.94%)
USD |
NASDAQ |
Nov 22, 16:00
16.94
+0.03
(+0.18%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Cash from Operations (Quarterly): -23.76M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -23.76M |
| June 30, 2024 | -30.14M |
| March 31, 2024 | -5.557M |
| December 31, 2023 | -0.629M |
| September 30, 2023 | -32.41M |
| June 30, 2023 | 50.81M |
| March 31, 2023 | -35.87M |
| December 31, 2022 | 160.26M |
| September 30, 2022 | -42.41M |
| June 30, 2022 | -36.82M |
| March 31, 2022 | -49.04M |
| December 31, 2021 | -42.50M |
| September 30, 2021 | -16.65M |
| June 30, 2021 | -32.94M |
| March 31, 2021 | -42.95M |
| December 31, 2020 | -6.632M |
| September 30, 2020 | -15.88M |
| June 30, 2020 | -8.494M |
| March 31, 2020 | -11.86M |
| December 31, 2019 | -7.538M |
| September 30, 2019 | -2.836M |
| June 30, 2019 | 9.34M |
| March 31, 2019 | -5.411M |
| December 31, 2018 | -5.763M |
| Date | Value |
|---|---|
| September 30, 2018 | -6.795M |
| June 30, 2018 | -7.841M |
| March 31, 2018 | -0.361M |
| December 31, 2017 | 5.001M |
| September 30, 2017 | -1.73M |
| June 30, 2017 | 1.233M |
| March 31, 2017 | -4.964M |
| December 31, 2016 | 12.36M |
| September 30, 2016 | -6.675M |
| June 30, 2016 | -4.106M |
| March 31, 2016 | -4.437M |
| December 31, 2015 | 22.16M |
| September 30, 2015 | -5.383M |
| June 30, 2015 | -3.891M |
| March 31, 2015 | -4.595M |
| December 31, 2014 | -7.741M |
| September 30, 2014 | -9.489M |
| June 30, 2014 | -5.468M |
| March 31, 2014 | -5.628M |
| December 31, 2013 | -4.829M |
| September 30, 2013 | -1.988M |
| June 30, 2013 | -0.355M |
| March 31, 2013 | -0.181M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-49.04M
Minimum
Mar 2022
160.26M
Maximum
Dec 2022
-11.55M
Average
-20.21M
Median
Cash from Operations (Quarterly) Benchmarks
| Bioventus Inc | 10.32M |
| Fulcrum Therapeutics Inc | -19.07M |
| Pfizer Inc | 6.714B |
| AIM ImmunoTech Inc | -3.11M |
| Protalix BioTherapeutics Inc | 4.105M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.08M |
| Cash from Financing (Quarterly) | 0.693M |
| Free Cash Flow | -61.62M |
| Free Cash Flow Per Share (Quarterly) | -0.8811 |
| Free Cash Flow to Equity (Quarterly) | -23.84M |
| Free Cash Flow to Firm (Quarterly) | -23.84M |
| Free Cash Flow Yield | -13.53% |